Dropoetin 3000IU

CLASSIFICATION Glycoprotein Cytokine
ACNE No
WATER RETENTION No
HBR No
HEPATOTOXICITY No
AROMATIZATION No
MANUFACTURER Drogsan
WAREHOUSE International Warehouse 2
SUBSTANCE Erythropoietin ,

Dropoetin is prescribed for the management of anemia linked to chronic kidney failure in both pediatric and adult patients undergoing hemodialysis and peritoneal dialysis.

It is also indicated for treating severe renal-origin anemia with clinical symptoms in adult patients who have kidney insufficiency but are not yet on dialysis.

Additionally, Dropoetin is used to address anemia and reduce the need for blood transfusions in adult cancer patients (excluding those with myeloid malignancies) receiving chemotherapy.

Dropoetin is indicated for adult patients infected with HIV who are receiving zidovudine treatment and who have endogenous Dropoetin levels at or below 500 mU/ml.

In adults, Dropoetin is utilized to support autologous blood collection in predeposit programs, thus minimizing the likelihood of requiring allogeneic blood transfusions in patients with moderate anemia (with hematocrit levels of 33-39%, hemoglobin levels between 10-13 g/dL, and no iron deficiency) scheduled for major elective surgeries, especially if they are likely to need more blood than can be collected through autologous methods without Dropoetin. Treatment should be considered only when blood conservation options are either unavailable or inadequate for surgeries anticipated to require 4 or more units for females or 5 or more units for males.

Dropoetin is also indicated to enhance red blood cell production during the perisurgical period to reduce the need for allogeneic blood transfusions and rectify postoperative anemia in adult patients who are not iron deficient undergoing major elective orthopedic surgeries. Its use should be limited to patients with moderate anemia (e.g., hemoglobin levels of 10-13 g/dL) without access to an autologous donation program and who are expected to experience moderate blood loss (900 to 1800 ml).

Additionally, Dropoetin is indicated for the treatment of anemia in patients with Low or Intermediate-1 risk Myelodysplastic Syndrome (MDS), with candidates for therapy having a hemoglobin level below 10 g/dL.

Administer Dropoetin as prescribed by your healthcare provider. Refer to the medicine label for specific dosage instructions.

Dropoetin is accompanied by a Medication Guide; be sure to read it thoroughly and revisit it each time you refill your prescription.

Typically, Dropoetin is administered via injection at a doctor's office, hospital, or clinic. If you will be self-administering Dropoetin at home, a healthcare professional will instruct you on how to use it. Ensure you fully understand the administration process and follow the techniques you've been taught. If you have any questions, reach out to your healthcare provider.

When preparing a dose, follow the demonstrated protocol to avoid contaminating the vial, syringe, or medication. Avoid touching the rubber stopper of the vial or the syringe needle with your fingers.

Confirm you have the correct dose before injection.

Do not shake Dropoetin, and do not use it if it has been shaken or frozen.

Do not dilute Dropoetin and do not mix it with other solutions unless instructed by your doctor.

If you are using a single-dose vial, dispose of any remaining medication after administering your dose. Consult your doctor, pharmacist, or healthcare provider if you need clarification on single-dose vials.

Avoid using Dropoetin if it appears cloudy, discolored, contains particles, or if the vial is cracked or damaged.

Store this product, along with syringes and needles, out of reach of children and pets. Avoid reusing needles, syringes, or any other items. Inquire with your healthcare provider about proper disposal methods for these materials, and adhere to local disposal regulations.

Continue using Dropoetin even if you feel well and do not skip any doses.

If you miss a dose, contact your doctor promptly.

For any questions regarding the use of Dropoetin, feel free to consult your healthcare provider.

The following serious adverse reactions are elaborated upon in other sections of the label: